Immunome, Inc.
Status: Publicly traded
Direct answer
Immunome, Inc. is publicly traded on NASDAQ under the ticker IMNM.
Immunome, Inc. functions as a biopharmaceutical company dedicated to the discovery and advancement of antibody-based therapies for both cancer and infectious illnesses. A pivotal project in its oncology portfolio is IMM-ONC-01, which is engineered to target the IL-38 immune checkpoint – a protein originating from tumors that enables cancer cells to bypass the body's immune surveillance. Additionally, the company is...
Can you invest in Immunome, Inc.?
Yes. Immunome, Inc. trades publicly on NASDAQ as IMNM.
View deeper analysis
View detailed research on MarketSnap, including financials, valuation tools, and analyst context.
Open research for Immunome, Inc.
Detailed equity research is provided by MarketSnap.